What Parents Need to Know

The FDA has approved Tivicay PD (dolutegravir) for HIV-1 treatment from birth in newborns weighing at least 2 kg, offering an age-appropriate treatment option for infants during the critical early weeks of life.

For a baby born with HIV, the first weeks of life can be critical for starting effective treatment. A new FDA approval now allows Tivicay PD (dolutegravir) to be used from birth in newborns weighing at least 2 kg, expanding an age-appropriate treatment option for the youngest patients (1^✔ ✔Trusted Source
FDA Approves Drug to Treat HIV Infection in Newborns

Go to source

).

What the FDA Approval Means for Babies With HIV

The U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) for treating HIV-1 infection from birth in newborns who weigh at least 2 kg. The medicine is given as a dispersible tablet for oral suspension and must be used with other antiretroviral medicines.

The approval is important because newborns with HIV now have an age-appropriate treatment option from the first day of life. Previously, Tivicay and Tivicay PD were approved for older children, with the pediatric indication beginning at 4 weeks of age.

HIV attacks the immune system and can become life-threatening without treatment. Starting effective antiretroviral therapy early is therefore particularly important in infants, in whom untreated HIV can progress rapidly.

Who Can Receive Tivicay PD?

The new FDA indication covers newborns who meet both key criteria:

• Age: From birth up to 4 weeks
• Weight: At least 2 kg
• Condition: HIV-1 infection
• Use: In combination with other antiretroviral medicines

The approval also received Priority Review, reflecting the medical need for treatment options for this particularly vulnerable population.

The formulation is designed to be given as an oral suspension, making it more practical for newborns who cannot swallow conventional tablets.

What Evidence Supported the Newborn HIV Approval?

The FDA decision was supported by the IMPAACT 2023 study and pharmacokinetic modeling. The study included 48 newborns who had been exposed to HIV-1 and weighed at least 2 kg. They received Tivicay PD from birth for up to 6 weeks alongside standard antiretroviral treatment, with follow-up continuing for 16 weeks.

Researchers found that dolutegravir exposure in the newborns was similar to drug levels associated with effectiveness in adults. The safety findings were also considered consistent with the known safety profile in older pediatric and adult patients.

Why Is Early HIV Treatment So Important in Newborns?

An infant who acquires HIV can develop serious immune-system damage if treatment is delayed. Early diagnosis and antiretroviral treatment can suppress the virus and help protect the developing immune system.

One continuing challenge is distinguishing infants who have been exposed to HIV from those who are actually infected. Babies born to mothers with HIV require appropriate testing and follow-up because maternal antibodies can complicate conventional antibody-based testing during infancy.

The new approval addresses another part of the challenge: having a treatment formulation that can be used at the earliest stage of life when HIV infection is confirmed or treatment is otherwise clinically indicated.

How Does Dolutegravir Work Against HIV?

Dolutegravir belongs to a class of HIV medicines called integrase strand transfer inhibitors (INSTIs). It blocks HIV integrase, an enzyme the virus needs to insert its genetic material into human cells.

By interfering with this step of the viral life cycle, dolutegravir helps prevent HIV from establishing productive infection and allows combination antiretroviral therapy to suppress the virus.

Dolutegravir has also been used in older children and adults for many years. Tivicay was first approved for adults in 2013, while Tivicay PD was subsequently approved for younger children.

What Are the Important Safety Precautions?

Tivicay and Tivicay PD should not be used in patients who have previously experienced a hypersensitivity reaction to dolutegravir or who are taking dofetilide. Serious allergic reactions have been reported.

Healthcare professionals should also monitor for possible liver injury. Immune reconstitution syndrome has been reported during combination antiretroviral treatment, particularly as the recovering immune system begins responding to infections that were previously present.

Drug interactions are another important consideration. Certain medicines can reduce dolutegravir’s effectiveness or increase the risk of adverse effects, so caregivers should provide clinicians with a complete list of medicines the newborn is receiving.

Importantly, Tivicay tablets and Tivicay PD oral-suspension tablets cannot be substituted on a milligram-for-milligram basis. Dosing must therefore follow the specific formulation and prescribing instructions.

What Does This Approval Mean for HIV-Exposed and HIV-Infected Babies?

The approval expands the treatment window for dolutegravir to the first weeks of life and lowers the minimum weight for the Tivicay PD indication to 2 kg.

However, this does not mean every HIV-exposed newborn will automatically receive dolutegravir. Treatment decisions depend on the infant’s HIV status, exposure circumstances, weight, other medicines and clinical assessment.

The evidence supporting the approval also comes from a relatively small newborn study, with 48 participants and 16 weeks of follow-up. Longer-term monitoring will provide additional information about durability, safety and real-world use.

For now, the FDA authorization represents an important expansion of age-appropriate HIV treatment and gives clinicians another option for managing HIV infection at one of the most vulnerable stages of life.

Bottom Line

For babies born with HIV, treatment cannot wait. The FDA’s approval of Tivicay PD from birth gives clinicians an age-appropriate dolutegravir option for newborns weighing at least 2 kg. The evidence is based on a small newborn study, so continued monitoring remains important, but the approval fills an important treatment gap during the earliest and most vulnerable stage of life.

Reference:

1. FDA Approves Drug to Treat HIV Infection in Newborns – (https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns)

Source-Medindia